An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update
Expert Rev Clin Pharmacol. 2024 Mar 15:1-14. doi: 10.1080/17512433.2024.2330468. Online ahead of print.ABSTRACTINTRODUCTION: With newer anti-obesity medications (AOMs) being introduced at a rapid pace, it is prudent to make a concise and updated clinical practice document that may help busy clinicians in daily clinical practice. A group of metabolic physicians, diabetologists, endocrinologists, and bariatric surgeons assembled during the Integrated Diabetes and Endocrine Academy 2023 Congress (IDEACON, July 2023, Kolkata, India) to compile an update of pharmacotherapeutic options for managing people with obesity in India.A...
Source: Expert Review of Clinical Pharmacology - March 12, 2024 Category: Drugs & Pharmacology Authors: Subir Ray Nitin Kapoor Neeta Deshpande Sanjay Chatterjee Janardanan Kumar Om Tantia Ghanshyam Goyal Jagat Jyoti Mukherjee Awadhesh Kumar Singh Source Type: research

Anti-obesity medications: current and futureAn overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update
Expert Rev Clin Pharmacol. 2024 Mar 12. doi: 10.1080/17512433.2024.2330468. Online ahead of print.ABSTRACTINTRODUCTION: With newer anti-obesity medications (AOMs) being introduced at a rapid pace, it is prudent to make a concise and updated clinical practice document that may help busy clinicians in daily clinical practice. A group of metabolic physicians, diabetologists, endocrinologists, and bariatric surgeons assembled during the Integrated Diabetes and Endocrine Academy 2023 Congress (IDEACON, July 2023, Kolkata, India) to compile an update of pharmacotherapeutic options for managing people with obesity in India.AREAS ...
Source: Expert Review of Clinical Pharmacology - March 12, 2024 Category: Drugs & Pharmacology Authors: Subir Ray Nitin Kapoor Neeta Deshpande Sanjay Chatterjee Janardanan Kumar Om Tantia Ghanshyam Goyal Jagat Jyoti Mukherjee Awadhesh Kumar Singh Source Type: research

Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis
CONCLUSION: Exposure-efficacy relationships for IV and SC vedolizumab administration were comparable, confirming that both are equally effective during maintenance treatment.PMID:38441048 | DOI:10.1080/17512433.2024.2318465 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Geert D'Haens Maria Rosario Daniel Polhamus Nathanael L Dirks Chunlin Chen Krisztina Kisfalvi Christian Agboton S éverine Vermeire Brian G Feagan William J Sandborn Source Type: research

Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives
Expert Rev Clin Pharmacol. 2024 Feb 27. doi: 10.1080/17512433.2024.2319340. Online ahead of print.ABSTRACTINTRODUCTION: Treatment resistance poses a significant obstacle in oncology, especially in biliary tract cancer (BTC) and pancreatic cancer (PC). Current therapeutic options include chemotherapy, targeted therapy, and immunotherapy. Resistance to these treatments may arise due to diverse molecular mechanisms, such as genetic and epigenetic modifications, altered drug metabolism and efflux, and changes in the tumor microenvironment. Identifying and overcoming these mechanisms is a major focus of research: strategies bei...
Source: Expert Review of Clinical Pharmacology - February 27, 2024 Category: Drugs & Pharmacology Authors: Bel én Toledo Chiara Deiana Fabio Scian ò Giovanni Brandi Juan Antonio Marchal Macarena Per án Elisa Giovannetti Source Type: research